{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": true, "customPriceAlertConfidence": "HIGH", "earningsTimestamp": 1683059400, "earningsTimestampStart": 1692016200, "earningsTimestampEnd": 1692361800, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -4.76, "epsForward": -4.33, "epsCurrentYear": -4.5, "priceEpsCurrentYear": -0.22666666, "sharesOutstanding": 5052460, "bookValue": 2.885, "fiftyDayAverage": 0.98962, "fiftyDayAverageChange": 0.03038001, "fiftyDayAverageChangePercent": 0.030698664, "twoHundredDayAverage": 1.97983, "twoHundredDayAverageChange": -0.95983005, "twoHundredDayAverageChangePercent": -0.48480427, "marketCap": 5331356, "forwardPE": -0.23556583, "priceToBook": 0.35355285, "currency": "USD", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "PRE", "regularMarketChangePercent": 4.5403256, "regularMarketPrice": 1.02, "firstTradeDateMilliseconds": 1435066200000, "priceHint": 4, "exchange": "NCM", "shortName": "Qualigen Therapeutics, Inc.", "longName": "Qualigen Therapeutics, Inc.", "messageBoardId": "finmb_1436301", "regularMarketChange": 0.04429996, "regularMarketTime": 1684180520, "regularMarketDayHigh": 1.025, "regularMarketDayRange": "0.96 - 1.025", "regularMarketDayLow": 0.96, "regularMarketVolume": 21130, "regularMarketPreviousClose": 0.9757, "bid": 0.0, "ask": 0.0, "bidSize": 22, "askSize": 8, "fullExchangeName": "NasdaqCM", "financialCurrency": "USD", "regularMarketOpen": 0.96, "averageDailyVolume3Month": 191235, "averageDailyVolume10Day": 37890, "fiftyTwoWeekLowChange": 0.19, "fiftyTwoWeekLowChangePercent": 0.22891566, "fiftyTwoWeekRange": "0.83 - 6.5", "fiftyTwoWeekHighChange": -5.48, "fiftyTwoWeekHighChangePercent": -0.84307694, "fiftyTwoWeekLow": 0.83, "fiftyTwoWeekHigh": 6.5, "dividendDate": 1590451200, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.0 - Buy", "tradeable": false, "cryptoTradeable": false, "displayName": "Qualigen Therapeutics", "symbol": "QLGN"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "2042 Corte Del Nogal", "city": "Carlsbad", "state": "CA", "zip": "92011", "country": "United States", "phone": "760 918 9165", "website": "https://www.qualigeninc.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Qualigen Therapeutics, Inc., a biotechnology company, develops novel therapeutic products for the treatment of cancer and infectious diseases. It offers FastPack, a rapid diagnostic testing system. The company is developing QN-302 for the treatment of pancreatic ductal adenocarcinoma; QN-247, a DNA coated gold nanoparticle cancer drug candidate that targets various cancers; RAS-F, a small-molecule RAS oncogene protein-protein inhibitor that blocks RAS mutations and inhibits tumor formation; and STARS blood cleansing system, a DNA/RNA-based treatment device that removes tumor-produced compounds and viruses from a patient's blood. Qualigen Therapeutics, Inc. was founded in 1996 and is based in Carlsbad, California.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Michael S. Poirier", "age": 66, "title": "Chairman & CEO", "yearBorn": 1956, "fiscalYear": 2022, "totalPay": {"raw": 583180, "fmt": "583.18k", "longFmt": "583,180"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Amy S. Broidrick", "age": 63, "title": "Pres, Chief Strategy & Operating Officer and Director", "yearBorn": 1959, "fiscalYear": 2022, "totalPay": {"raw": 457642, "fmt": "457.64k", "longFmt": "457,642"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Dr. Tariq  Arshad M.B.A., M.D.", "age": 51, "title": "Sr. VP & Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2022, "totalPay": {"raw": 400138, "fmt": "400.14k", "longFmt": "400,138"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Christopher L. Lotz", "age": 56, "title": "VP of Fin., CFO & Corp. Sec.", "yearBorn": 1966, "fiscalYear": 2020, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Benedict M. Abugan", "title": "VP, Head of Diagnostics & Corp. Communications", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1672444800, "maxAge": 86400}}], "error": null}}